Brook Baker, a law pro­fessor at North­eastern Uni­ver­sity in Boston, said he doubts the phar­ma­ceu­tical industry will pull back much on its invest­ments in India based on the deci­sion. The country will still grant 20 year patents on new, inno­v­a­tive drugs and a growing middle class with chronic dis­eases will pro­vide many busi­ness oppor­tu­ni­ties, he said.

I think there is plenty of incen­tives for them to come to India,” Baker said in a tele­phone inter­view. “They always cry doomsday and say no one will invest in India because it isn’t an investor-​​friendly country. But com­pa­nies will invest in India because they can make money there.”

Read the article at Bloomberg →